Skip Navigation


European Heart Journal Advance Access originally published online on October 31, 2006
European Heart Journal 2006 27(24):3065-3072; doi:10.1093/eurheartj/ehl354
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
27/24/3065    most recent
ehl354v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Mollet, A.
Right arrow Articles by Boudjemline, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mollet, A.
Right arrow Articles by Boudjemline, Y.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2006. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Development of a device for transcatheter pulmonary artery banding: evaluation in animals

Alix Mollet1, Bertrand Stos1, Damien Bonnet1,2, Daniel Sidi1,2 and Younes Boudjemline1,2,*

1 Pediatric Cardiology, Assistance Publique des Hôpitaux de Paris, Necker For Sick Children, 149, rue de Sèvres, 75015 Paris cedex, France
2 INSERM EMIU 0016, Necker University, Paris, France

Received 19 June 2006; revised 15 September 2006; accepted 12 October 2006; online publish-ahead-of-print 31 October 2006.

* Corresponding author. Tel: +33 1 44 49 45 89; fax: +33 1 44 49 57 24. E-mail address: younes.boudjemline{at}nck.ap-hop-paris.fr

Aims Pulmonary artery banding (PAB) is the first palliation in infants with complex congenital heart disease and elevated pulmonary blood flow. In older patients with corrected transposition of the great arteries, it may be used to retrain the left ventricle. To date, the only option is surgical. We report the development and the evaluation of a device for transcatheter PAB.

Methods and results We intended to implant a pulmonary artery (PA) reducer percutaneously between the native pulmonic valve and the pulmonary bifurcation. Immediately following its insertion, we planned to implant a balloon expandable stent inside the restriction to calibrate the banding. Sheep were sacrificed acutely (group 1, n=6) and after 1 month of follow-up (group 2, n=6), the reducer was implanted successfully in all animals. It allowed the PA diameter to be reduced from 25 to 10.5 mm. Bare stents were successfully delivered inside the reducer. No paraprosthetic leak was found by injecting contrast dye. After the insertion procedure, signs of intolerance to obstruction were present in all animals and prompted us to dilate the stents from 12 to 16 mm. One animal from group 1 died before a balloon dilatation could be achieved. In the animals from group 2, the mean systolic gradient was 19 and 34.8 mmHg, respectively, at early and late evaluation.

Conclusion Implantation of a PA reducer is possible in sheep, through a transcatheter approach allowing intravascular PAB. Miniaturization of the device is necessary to enlarge its use from adulthood to childhood.

Key Words: Congenital heart disease • Pulmonary artery banding • Catheter-based coronary and valvular interventions • Experimental study


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.